Insmed (INSM) Tops Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Insmed (INSM) Tops Q1 EPS by 8c

Insmed Reports First Quarter 2022 Financial Results and Provides Business Update

May 5, 2022 7:30 AM EDT

--ARIKAYCE® (amikacin liposome inhalation suspension) Achieves 32% Year Over Year Growth for the First Quarter of 2022 with Total Revenue of $53.1 Million--

--Seven Clinical Trials Underway; Enrollment on Track in Brensocatib Phase 3 ASPEN Study and ARIKAYCE Post-Marketing Studies (ARISE and ENCORE)--

--Company Reiterates Revenue Guidance of at Least 30% Growth in 2022 and Cash Runway into 2024 to Support Ongoing Programs--

BRIDGEWATER, N.J., May 5, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the... More